Abstract:Background The inflammatory biomarker YKL‐40 has previously been studied as a potential risk marker in cardiovascular disease. We aimed to assess the prognostic reclassification potential of serum YKL‐40 in patients with stable coronary artery disease. Methods and Results The main study population was the placebo group of the CLARICOR (Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease) trial. The primary outcome was a composite of acute myocardial infarction, unstable angina pectoris, cerebrovascular disease, and all‐cause mortality. We used Cox proportional hazards regression models adjusted for C‐reactive protein level and baseline cardiovascular risk factors. Improvement in prediction by adding serum YKL‐40 to the risk factors was calculated using the Cox‐Breslow method and c‐statistic. A total of 2200 patients were randomized to placebo, with a follow‐up duration of 10 years. YKL‐40 was associated with an increased risk of the composite outcome (hazard ratio per unit increase in (YKL‐40) 1.13, 95% CI 1.03–1.24, P =0.013) and all‐cause mortality (hazard ratio 1.32, 95% CI 1.17–1.49, P <0.0001). Considering whether a composite‐outcome event was more likely to have, or not have, occurred to date, we found 68.4% of such predictions to be correct when based on the standard predictors, and 68.5% when serum YKL‐40 was added as a predictor. Equivalent results were obtained with c‐statistics. Conclusions Higher serum YKL‐40 was independently associated with an increased risk of adverse cardiovascular outcomes and mortality. Addition of YKL‐40 did not improve risk prediction in patients with stable coronary artery disease. Clinical Trial Registration URL: https://www.clinicaltrials.gov/ . Unique identifier: NCT00121550. Clinical Perspective What Is New? In patients with stable coronary artery disease, higher YKL‐40 is significantly related to cardiovascular events and mortality over 10 years of follow‐up after adjustment for standard predictors and high‐sensitivity C‐reactive protein, possibly reflecting high‐risk atherosclerotic progression and inflammation. What Are the Clinical Implications? In reclassification analysis YKL‐40 did not improve prognostic accuracy compared with predictions based only on standard predictors, and the value of measuring YKL‐40 to support clinical decision making appears limited. Introduction The desire to better assess prognosis in patients with cardiovascular disease (CVD) and further advance the understanding of the underlying atherosclerotic process has prompted the emergence of numerous potential CVD biomarkers. Many candidates have demonstrated consistent association with standard CVD outcome measures. Nonetheless, auxiliary predictive potential in addition to that offered by standard available clinical characteristics is in many cases absent or unclear, hindering translation of results into specific changes in patient management strategies. 1 , 2 , 3 However, in addition to possible utility in risk prediction, biomarker studies may unravel new key factors in CVD pathogenesis such as proinflammatory effectors, and ultimately help identify new potential upstream treatment targets. 4 , 5 YKL‐40, also known as chitinase‐3‐like‐1, is an inflammatory biomarker which has gathered increasing evidence during the past 2 decades. 6 It is considered an acute‐phase protein and has been specifically linked to the inflammatory process in the atherosclerotic plaque, 7 diseases of extracellular remodeling and fibrosis, 8 angiogenesis and regulation of proinflammatory cascades. 9 , 10 YKL‐40 has recently been associated with development of hyperlipidemia and ischemic stroke in a study of almost 10 -Abstract Truncated-

Association of YKL-40 levels with carotid atherosclerotic plaque stability

YKL-40 Is Associated With Ultrasound-Determined Carotid Atherosclerotic Plaque Instability

Associations among Carotid Plaque Progression, Cerebrovascular/ Cardiovascular Diseases and LDL-C/non-HDL-C Goal Achievement in Diabetic Patients: A Retrospective Cohort Study

Non-HDL-C/HDL-C Ratio is Associated with Carotid Plaque Stability in General Population: A Cross-Sectional Study

YKL-40 levels increase with declining ankle-brachial index and are associated with long-term cardiovascular mortality in peripheral arterial disease patients

Homocysteine and Carotid Plaque Stability: A Cross-Sectional Study in Chinese Adults

Prognostic Performance of Serum YKL-40 for One-Year Clinical Outcomes in Acute Ischemic Stroke

Association between serum YKL-40 levels and endothelial function in hypertensive patients]

Prognosis and Reclassification by YKL-40 in Stable Coronary Artery Disease.

Association of LDLc to HDLc ratio with carotid plaques in a community-based population with a high stroke risk: A cross-sectional study in China

The value of Lp(a) and TG/HDLC in peripheral blood to assess the stability of carotid plaque in patients with ischemic stroke

YKL-40: a potential biomarker for osteoarthritis.

Triglyceride-Glucose Index Is Related to Carotid Plaque and Its Stability in Nondiabetic Adults: A Cross-Sectional Study

[Prediction Value of Blood Lipid Levels on Newly Identified Carotid Plaque in Middle-Aged and Elderly Chinese Population].

[Correlation analysis of carotid adipose tissue density and plaque stability in patients with carotid artery stenosis]

Value evaluation of serum (sdLDLc*HCYc)/HDLc ratio in the stability of intracranial arterial plaques in patients with acute cerebral infarction

E0267 Prediction of the Newly-Identified Carotid Plaque with Blood Lipid Levels in Chinese Elderly Population

Study on the Relationship Between β2 Macroglobulin, Small Density, Low-density Lipoprotein and Carotid Plaque Instability after Acute Thrombolysis in Patients with Ischemic Stroke

Association between cumulative exposure to different lipid parameters and risk of newly developed carotid plaque

Additive Effect Between Homocysteine and Low-Density-lipoprotein Cholesterol Upon Incidence of Novel Carotid Plaque Formation: Data from a Chinese Community-Based Cohort

[Relationship between lipid metabolism molecules in plasma and carotid atheroscle-rotic plaques, traditional cardiovascular risk factors, and dietary factors].